Colon Rectum

x1.85x2.35x1.87x2.48 1:111:8 1:11

Rectum

IGF-1 Insulin

Colonic polyp

60%

Colonoscopy

Colonoscopy : Regular vs virtual

Mitochondria DNA Nucleus Golgi vesicles Endoplasmic reticulum Lysosome Cytoplasm Cytoskeleton Peroxisome Proteasome TPP(Thiamine) NAD(Nicotinamide) FAD B2(Riboflavin) Folic acid B12 Vit C Vit E

.1.2

N-acetyl transferase

HIF-1 VEGF PDGF G-CSF VEGF EGF

VEGF

EGF VEGF

EGF VEGF Avastin Erbitux

Adjuvant therapy for Stage II colorectal cancer patients with no risk factors. 85% 15% 85% 2% 5FU Gain in DFS Adjuvant therapy for stage II patients with colorectal cancer with no risk factors is probably not recommended despite a 2% gain in disease free survival. Cure by surgery Relapse 2% 13% DFS with chemo 85% 87%

DFS with chemo 70% 80.0% Adjuvant therapy for Stage II colorectal cancer patients with risk factors. 70% 30% Cure by surgery Relapse 70% 2-3% 5FU 7.2% 7.2%Oxaliplatin Gain in DFS 20.0% Risk factors 1.T4 2.Obstruction 3.Perforation 4.G3 5.Vascular invasion 6.<10 examined lymph nodes 7. Age <50 y Adjuvant therapy for stage II patients with colorectal cancer with risk factors should be probably administered because of a 10% gain in Disease free survival with 5FU and Oxaliplatin. 10.4%

60%

Adjuvant therapy for Stage III (anyTN1) colorectal cancer patients. 60% 40% Cure by surgery Relapse Gain in DFS Adjuvant therapy for stage III (T3N1) patients with colorectal cancer is recommended because of a 19.2% gain in disease free survival with 5FU and Oxaliplatin. 19.2% 60% 12% 5FU 12% 7.2% Oxaliplatin 7.2% 20.8% DFS with chemo 60% 79.2%

Adjuvant therapy for Stage III (anyTN2) colorectal cancer patients. 35% 65% 38% Cure by surgery Relapse Gain in DFS Adjuvant therapy for stage III (T3N1) patients with colorectal cancer is recommended because of a 26.5% gain in disease free survival with 5FU and Oxaliplatin. 26.5% 15% 12-15% 5FU 11.5% 12.0% FOLFOX DFS with chemo 35% 61.5%